Endomyocardial Biopsy Market Size - By Product (Forceps, Accessories), By Tip (Maxi-curved, Straight, Pre-curved), By End-use & - Global Forecast to 2032

Endomyocardial Biopsy Market Size - By Product (Forceps, Accessories), By Tip (Maxi-curved, Straight, Pre-curved), By End-use & - Global Forecast to 2032

Endomyocardial Biopsy Market size is anticipated to expand at 6.8% CAGR from 2023 to 2032 driven by the rising prevalence of heart-related conditions, including cardiomyopathies and heart transplant monitoring coupled with the higher need for diagnostic and monitoring tools.

Lately, patients have grown increasingly aware about the significance of cardiac assessments, including endomyocardial biopsies. Physicians are also recognizing the value of early detection and precise monitoring of heart conditions, further fueling the recommendation and prescription of endomyocardial biopsies. Moreover, independent clinical laboratory platforms are increasing their diagnostic testing capabilities and services to support the market development. To cite an instance, in September 2023, Adicon Holdings Limited, a major independent clinical laboratory firm, started providing liquid biopsy tests from Guardant Health, a leading precision oncology company, in China to accelerate clinical R&D of innovative cancer therapeutics.

The overall endomyocardial biopsy market is segmented in terms of product, tip, end-use, and region.

Based on product, the industry value from the accessories segment is poised to gain significant traction between 2023 and 2032. Endomyocardial biopsy procedures rely heavily on specialized accessories, such as biopsy forceps, catheters, and needles. The continuous demand for these critical tools is driven by the increasing incidence of cardiovascular diseases, further necessitating accurate diagnosis and monitoring. Technological advancements in biopsy accessories, such as improved design and materials for enhanced safety and precision will also stimulate the segment growth.

In terms of end-use, the ambulatory surgical centers (ASCs) segment generated considerable revenue in the endomyocardial biopsy industry in 2022 and is projected to witness substantial growth through 2032. This is owing to the increasing preference for cardiac procedures, including endomyocardial biopsies at ASCs due to their cost-effectiveness, convenience, and shorter patient stays. The rising advancements in minimally invasive techniques for endomyocardial biopsies driven by the surging focus on providing outpatient care will contribute to the segment expansion.

Asia Pacific endomyocardial biopsy market is slated to record robust growth between 2023 and 2032 attributed to the rising prevalence of cardiovascular diseases, mainly in India and China. Increasing awareness, improved healthcare infrastructure, and greater access to advanced diagnostic procedures are driving the demand for endomyocardial biopsies. It has been estimated that by 2060, there will be more than 1.2 billion Asians aged 65 years and above. This growing geriatric population in the region may contribute to the increased need for cardiac assessment and monitoring, further propelling the regional industry growth.